IDH1 and glioblastoma: Compared to traditional molecular prognostic markers, such as IDH1 mutation and MGMT promoter methylation status (23), these hematological inflammatory markers can conveniently evaluate the prognosis of GBM patients in order to guide clinicians' therapeutic decisions and patient management.